Skip to main content
Top
Published in: Rheumatology International 12/2012

01-12-2012 | Original Article

Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

Authors: Kamal Esalatmanesh, Raika Jamali, Arsia Jamali, Bardia Jamali, Mohammadreza Nikbakht

Published in: Rheumatology International | Issue 12/2012

Login to get access

Abstract

To define the relationship between serum anti-cyclic citrullinated peptide antibodies (anti-CCP) and disease activity, and to construct a new disease activity index by using anti-CCP in rheumatoid arthritis (RA). One hundred and five RA patients were included. Disease activity based on DAS28-ESR and serum anti-CCP was measured. There was correlation between serum anti-CCP and DAS28-ESR. (R 2 = 0.71, P value < 0.01). New disease activity index was developed by replacing anti-CCP with ESR in DAS28-ESR. There was correlation between new model and DAS28-ESR. (R 2 = 0.91, P value < 0.01) The new composite index best cut-off values corresponding to DAS28-ESR values of 2.6, 3.2, and 5.1 were 3.21, 3.38, and 4.74, respectively. There was agreement between new model and DAS28-ESR for determination of patients in different disease activity categories. (Kappa = 0.71, P value < 0.01). The new disease activity index that applies serum anti-CCP may predict disease activity in RA.
Literature
1.
go back to reference Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M, Karimifar M, Essalatmanesh K, Barghamdi M, Noorolahzadeh E, Dahaghin S, Rasker JJ (2009) The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 28:1267–1274PubMedCrossRef Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M, Karimifar M, Essalatmanesh K, Barghamdi M, Noorolahzadeh E, Dahaghin S, Rasker JJ (2009) The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 28:1267–1274PubMedCrossRef
2.
go back to reference Zamani B, Jamali R, Ehteram H (2010) Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis. Rheumatol Int. doi:10.1007/s00296-010-1602-3 Zamani B, Jamali R, Ehteram H (2010) Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis. Rheumatol Int. doi:10.​1007/​s00296-010-1602-3
3.
go back to reference Erer B, Yilmaz G, Yilmaz FM, Koklu S (2009) Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy. Rheumatol Int 29:651–654PubMedCrossRef Erer B, Yilmaz G, Yilmaz FM, Koklu S (2009) Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy. Rheumatol Int 29:651–654PubMedCrossRef
6.
go back to reference Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G, Richards JS, Johnson D, Caplan L, Reimold A, Hooker R, Mikuls TR (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292–1297PubMedCrossRef Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G, Richards JS, Johnson D, Caplan L, Reimold A, Hooker R, Mikuls TR (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292–1297PubMedCrossRef
7.
go back to reference Rodríguez-Rodríguez L, Lamas JR, Varadé J, López-Romero P, Tornero-Esteban P, Abasolo L, de la Concha EG, Jover JA, Urcelay E, Fernández-Gutiérrez B (2011) Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatol Int 31:409–413PubMedCrossRef Rodríguez-Rodríguez L, Lamas JR, Varadé J, López-Romero P, Tornero-Esteban P, Abasolo L, de la Concha EG, Jover JA, Urcelay E, Fernández-Gutiérrez B (2011) Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatol Int 31:409–413PubMedCrossRef
8.
go back to reference Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW (2011) Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 38:242–246PubMedCrossRef Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW (2011) Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 38:242–246PubMedCrossRef
9.
go back to reference Emery P, Gabay C, Kraan M, Gomez-Reino J (2007) Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 27:793–806PubMedCrossRef Emery P, Gabay C, Kraan M, Gomez-Reino J (2007) Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 27:793–806PubMedCrossRef
10.
go back to reference Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E, Sierakowski S, Szmitkowski M (2010) Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 55:80–85PubMedCrossRef Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E, Sierakowski S, Szmitkowski M (2010) Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 55:80–85PubMedCrossRef
11.
go back to reference Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA (2011) Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study. J Rheumatol 38:44–52PubMedCrossRef Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA (2011) Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study. J Rheumatol 38:44–52PubMedCrossRef
12.
go back to reference Nishimoto N, Takagi N (2010) Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol 20:539–547PubMedCrossRef Nishimoto N, Takagi N (2010) Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol 20:539–547PubMedCrossRef
13.
go back to reference Ryu HJ, Takeuchi F, Kuwata S, Kim YJ, Lee EY, Lee EB, Song YW (2011) The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol Int 31:315–319PubMedCrossRef Ryu HJ, Takeuchi F, Kuwata S, Kim YJ, Lee EY, Lee EB, Song YW (2011) The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol Int 31:315–319PubMedCrossRef
14.
go back to reference Önder B, Kurtaran A, Kimyon S, Selçuk B, Akyüz M (2009) Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 30:223–227PubMedCrossRef Önder B, Kurtaran A, Kimyon S, Selçuk B, Akyüz M (2009) Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 30:223–227PubMedCrossRef
15.
go back to reference Landmann T, Kehl G, Bergner R (2010) The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 29:1449–1453PubMedCrossRef Landmann T, Kehl G, Bergner R (2010) The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 29:1449–1453PubMedCrossRef
16.
go back to reference Vanichapuntu M, Phuekfon P, Suwannalai P, Verasertniyom O, Nantiruj K, Janwityanujit S (2010) Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int 30:755–759PubMedCrossRef Vanichapuntu M, Phuekfon P, Suwannalai P, Verasertniyom O, Nantiruj K, Janwityanujit S (2010) Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int 30:755–759PubMedCrossRef
17.
go back to reference Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M (2008) The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. Mikrobiyol Bul 42:669–674PubMed Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M (2008) The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. Mikrobiyol Bul 42:669–674PubMed
18.
go back to reference Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970PubMedCrossRef Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970PubMedCrossRef
19.
go back to reference Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, Ghannouchi M, Mokhtar F, Ghedira I (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125–1130PubMedCrossRef Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, Ghannouchi M, Mokhtar F, Ghedira I (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125–1130PubMedCrossRef
20.
go back to reference van der Heijde DM, van’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181PubMedCrossRef van der Heijde DM, van’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181PubMedCrossRef
21.
go back to reference Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
22.
go back to reference Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, Taniguchi A, Yamanaka H (2010) Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. doi:10.1007/s00296-010-1671-3 Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, Taniguchi A, Yamanaka H (2010) Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. doi:10.​1007/​s00296-010-1671-3
23.
go back to reference Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39PubMedCrossRef Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39PubMedCrossRef
24.
go back to reference Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23PubMedCrossRef Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23PubMedCrossRef
25.
go back to reference Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI (2007) Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord: 8:37CrossRef Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI (2007) Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord: 8:37CrossRef
26.
go back to reference Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37:329–336PubMedCrossRef Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37:329–336PubMedCrossRef
27.
go back to reference Kolarz B, Majdan M, Dryglewska M, Darmochwal-Kolarz D (2010) Antibodies against cyclic citrullinated peptide don’t decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-010-1509-z Kolarz B, Majdan M, Dryglewska M, Darmochwal-Kolarz D (2010) Antibodies against cyclic citrullinated peptide don’t decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. Rheumatol Int. doi:10.​1007/​s00296-010-1509-z
28.
go back to reference Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M (2010) Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis. Rheumatol Int 30:451–454PubMedCrossRef Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M (2010) Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis. Rheumatol Int 30:451–454PubMedCrossRef
29.
go back to reference Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62PubMedCrossRef Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62PubMedCrossRef
30.
go back to reference Kogure T, Sato H, Kishi D, Ito T, Tatsumi T (2009) Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis. Rheumatol Int 29:1441–1447PubMedCrossRef Kogure T, Sato H, Kishi D, Ito T, Tatsumi T (2009) Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis. Rheumatol Int 29:1441–1447PubMedCrossRef
31.
go back to reference van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, n Mil AH (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, n Mil AH (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef
32.
go back to reference Wagner E, Skoumal M, Bayer PM, Klaushofer K (2009) Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 29:1315–1321PubMedCrossRef Wagner E, Skoumal M, Bayer PM, Klaushofer K (2009) Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 29:1315–1321PubMedCrossRef
Metadata
Title
Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
Authors
Kamal Esalatmanesh
Raika Jamali
Arsia Jamali
Bardia Jamali
Mohammadreza Nikbakht
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2282-3

Other articles of this Issue 12/2012

Rheumatology International 12/2012 Go to the issue